Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials

被引:12
|
作者
Canafax, Daniel M. [2 ]
Bhanegaonkar, Abhijeet [3 ]
Bharmal, Murtuza [4 ]
Calloway, Michael [1 ]
机构
[1] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA
[2] XenoPort Inc, Santa Clara, CA USA
[3] W Virginia Univ, Sch Pharm, Morgantown, WV 26506 USA
[4] Quintiles, Rockville, MD USA
关键词
QUALITY-OF-LIFE; MEDICAL OUTCOMES; SYNDROME RLS; EPIDEMIOLOGY; DIAGNOSIS; DISEASE; SCALE;
D O I
10.1186/1471-2377-11-48
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Because of the subjective nature of Restless Legs Syndrome (RLS) symptoms and the impact of these symptoms on sleep, patient-reported outcomes (PROs) play a prominent role as study endpoints in clinical trials investigating RLS treatments. The objective of this study was to validate a new measure, the Post Sleep Questionnaire (PSQ), to assess sleep dysfunction in subjects with moderate-to-severe RLS symptoms. Methods: Pooled data were analyzed from two 12-week, randomized, placebo-controlled trials of gabapentin enacarbil (N = 540). At baseline and Week 12, subjects completed the PSQ and other validated health surveys: IRLS Rating Scale, Clinical Global Impression of Improvement (CGI-I), Profile of Mood States (POMS), Medical Outcomes Study Scale-Sleep (MOS-Sleep), and RLS-Quality of Life (RLSQoL). Pooled data were used post hoc to examine the convergent, divergent, known-group validity and the responsiveness of the PSQ. Results: Convergent validity was demonstrated by significant correlations between baseline PSQ items and total scores of IRLS, POMS, RLSQoL, and the MOS-Sleep Scale (p = 0.007 each). Divergent validity was demonstrated through the lack of significant correlations between PSQ items and demographic characteristics. Correlations (p < 0.0001) between RLS severity groups and PSQ items demonstrated known-group validity. Mean changes in investigator-and subject-rated CGI-I scores for each PSQ item (p < 0.0001) demonstrated the PSQ's responsiveness to patient change as reported by their care provider. Conclusions: Although these analyses were potentially limited by the use of clinical trial data and not prospective data from a study conducted solely for validation purposes, the PSQ demonstrated robust psychometric properties and is a valid instrument for assessing sleep and sleep improvements in subjects with moderate-to-severe RLS symptoms.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] PRAMIPEXOLE IS WELL-TOLERATED IN THE TREATMENT OF RESTLESS LEGS SYNDROME: POOLED RESULTS FROM TWO RECENT PLACEBO-CONTROLLED TRIALS
    Albrecht, S.
    Koester, J.
    SLEEP, 2009, 32 : A296 - A296
  • [42] Pramipexole is effective in the treatment of restless legs syndrome (RLS): Results of a 6 week, multi-centre, double-blind, and placebo-controlled study
    Oertel, W
    Stiasny-Kolster, K
    MOVEMENT DISORDERS, 2005, 20 : S58 - S58
  • [43] Impact of topiramate migraine prophylaxis on workplace productivity: Results from two US randomized, double-blind, placebo-controlled, multicenter trials
    Lofland, Jennifer H.
    Gagne, Joshua J.
    Pizzi, Laura T.
    Rupnow, Marcia
    Silberstein, Stephen D.
    JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2007, 49 (03) : 252 - 257
  • [44] Impact of topiramate for migraine prophylaxis on workplace productivity: Results from two US randomized, double-blind, placebo-controlled, multicenter trials
    Gagne, JJ
    Lofland, JH
    Rupnow, M
    Smith, KD
    Poston, S
    Pizzi, LT
    VALUE IN HEALTH, 2006, 9 (03) : A23 - A23
  • [45] Cardiovascular Safety of Prucalopride in Healthy Subjects: Results from Two Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trials
    Boyce, Malcolm J.
    Kerstens, Rene
    Beyens, Greet
    Ausma, Jannie
    Vandeplassche, Lieve
    GASTROENTEROLOGY, 2009, 136 (05) : A535 - A535
  • [46] Severe bleeding in patients with severe chronic ITP: Results from two double-blind, placebo-controlled, randomized clinical trials
    Bussel, J.
    Newland, A.
    Provan, A.
    Aivado, M.
    Stone, N.
    Poulin, R.
    Mayer, B.
    Arning, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 282 - 282
  • [47] A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Pharmacokinetics, Efficacy, and Safety of Gabapentin Enacarbil in Subjects With Restless Legs Syndrome
    Lal, Ritu
    Ellenbogen, Aaron
    Chen, Dan
    Zomorodi, Katie
    Atluri, Harisha
    Luo, Wendy
    Tovera, James
    Hurt, Janet
    Bonzo, Daniel
    Lassauzet, Marie-Liesse
    Vu, Amanda
    Cundy, Kenneth C.
    CLINICAL NEUROPHARMACOLOGY, 2012, 35 (04) : 165 - 173
  • [48] EFFECTIVE TREATMENT OF IDIOPATHIC RESTLESS LEGS SYNDROME WITH PREGABALIN: A TWELVE-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH CLINICAL AND POLYSOMNOGRAPHIC ASSESSMENT
    Garcia-Borreguero, D.
    Larrosa, O.
    Alvares, J.
    Pascual, M.
    Fernandez, C.
    Palacios, C.
    SLEEP, 2009, 32 : A294 - A294
  • [49] A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials
    Moore, Angela Yen
    Hurley, Kara
    Moore, Stephen Andrew
    ANTIBIOTICS-BASEL, 2023, 12 (01):
  • [50] Botulinum toxin in Restless Leg Syndrome - A Randomized Double-Blind Placebo-Controlled Study
    Mittal, S.
    Machado, D.
    RIchardson, D.
    Dubey, D.
    Jabbari, B.
    MOVEMENT DISORDERS, 2018, 33 : S494 - S494